Zydelig (idelalisib) is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Zydelig is used together with rituximab (Rituxan) to treat chronic lymphocytic leukemia, and certain types of lymphoma.
Zydelig is sometimes given after at least two other cancer treatments did not work or have stopped working.
Zydelig was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis to treat lymphoma. In clinical studies, some people responded to this medicine, but further studies are needed.
